Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ciba urges FDA to take "class approach" in reviewing nicotine patch Rx-to-OTC switches.

This article was originally published in The Tan Sheet

Executive Summary

CIBA URGES "CLASS APPROACH" TO FDA REVIEW OF NICOTINE PATCH SWITCHES in a presentation during the open hearing portion of the Nonprescription Drugs Advisory Committee's April 19 meeting. The FDA advisory committee unanimously recommended clearing both McNeil's Nicotrol patch and SmithKline Beecham's Nicoderm patch for over-the-counter marketing at the meeting .
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel